Stifel Starts Summit Therapeutics plc (SMMT) at Buy, 'ivonescimab has high probability-of-success'

March 25, 2024 4:08 PM EDT Send to a Friend
(Updated - March 25, 2024 4:09 PM EDT)

Stifel analyst Brad Canino initiates coverage on Summit Therapeutics plc (NASDAQ ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login